Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MEDI-1814 by AstraZeneca for Alzheimer's Disease: Likelihood of Approval
MEDI-1814 is under clinical development by AstraZeneca and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...
Acalabrutinib maleate by AstraZeneca for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Acalabrutinib maleate by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...
Acalabrutinib maleate by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...
Ceralasertib by AstraZeneca for Metastatic Colorectal Cancer: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Durvalumab by AstraZeneca for Vulvar Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Vaginal Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Anal Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Anal Cancer. According to GlobalData, Phase II...
MEDI-0457 by AstraZeneca for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
MEDI-0457 is under clinical development by AstraZeneca and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to...
Anifrolumab by AstraZeneca for Hidradenitis Suppurativa: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Benralizumab by AstraZeneca for Rhinosinusitis: Likelihood of Approval
Benralizumab is under clinical development by AstraZeneca and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs...
TBO-309 by AstraZeneca for Acute Ischemic Stroke: Likelihood of Approval
TBO-309 is under clinical development by AstraZeneca and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase...
Adavosertib by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
MEDI-7352 by AstraZeneca for Diabetic Neuropathic Pain: Likelihood of Approval
MEDI-7352 is under clinical development by AstraZeneca and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase...
Oleclumab by AstraZeneca for Solid Tumor: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Volrustomig?
Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Cervical Cancer. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's MEDI-7352?
MEDI-7352 is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Diabetic Neuropathic Pain. According to...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Datopotamab deruxtecan?
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Pre-Registration program in Non-Small Cell Lung Cancer....
Adavosertib by AstraZeneca for Vaginal Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase I for Vaginal Cancer. According to GlobalData, Phase I...
Adavosertib by AstraZeneca for Cervical Cancer: Likelihood of Approval
Adavosertib is under clinical development by AstraZeneca and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...